Alnylam Pharmaceuticals ALNY Total TTR — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's total ttr — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's total TTR — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported total TTR — total revenues of $1.03B in Q2 2026.
- How has Alnylam Pharmaceuticals's total TTR — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's total TTR — total revenues increased by 89.2% year-over-year, from $544.49M to $1.03B.
- What is the long-term trend for Alnylam Pharmaceuticals's total TTR — total revenues?
- Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's total TTR — total revenues has grown at a 65.1% compound annual growth rate (CAGR), from $912.38M to $2.49B.
- What does total TTR — total revenues mean?
- This metric represents the aggregate net product revenue generated from the company's portfolio of therapeutics targeting transthyretin-mediated (TTR) amyloidosis. It serves as a primary indicator of the commercial adoption and market penetration of the company's RNAi-based treatments for this specific disease area. Monitoring this revenue stream is essential for evaluating the company's core franchise performance and its ability to maintain leadership in the rare disease therapeutic market.